'Flashback' arena tour begins Wednesday in Alabama
Music by Jimi Hendrix, Pink Floyd, Led Zeppelin, the Doors, Janis Joplin and Deep Purple, among others, will be performed live by the Mystical Orchestra as part of "Flashback -- the Classic Rock Experience." The well-nigh 50-date U.S. arena circuit launches Wednesday at the Mobile Civic Center in Mobile, Ala.
Inspired partly by Paul O'Neill's Trans-Siberian Orchestra, which features a full rock ring, a string section, multiple vocalists and a laser/light show, "Flashback" boasts 14 musicians and singers, along with an 11-piece string and horn section. The concert's close to 30-song countersink features such classics as Hendrix's "Purple Haze," Led Zeppelin's "Stairway to Heaven," Pink Floyd's "Money," and the Doors' "Light My Fire."
"I don't think there's ever been a large-scale arena event produced like this," veteran soldier promoter and "Flashback" manufacturer Rick Bowen said. "I tried to pick artists that were either not going to be able to circuit, or were touring very little."
The idea to make "Flashback" came after visual perception a TSO concert in 2006, Bowen said. "In a lot of shipway (TSO has) plowed the ground for us, because we combine rock music and orchestra music together," he aforementioned. "We've just taken it to the classic rock platform and tried to play the very best of the music in the geological era of the late '60s and early '70s."
"Flashback," which cost about $5.5 million to produce, will feature six-spot truckloads of LED light, lasers, pyrotechnics and 30-foot inflated zeppelin that will hang in the centre of arenas. Additionally, seven video screens will play vintage video footage from some of the artists whose medicine is featured during the nearly three-hour show, according to Bowen, whose Mystic Music Enterprises is promoting the tour.
The first leg of "Flashback" will inspect 6,000- to 25,000-seat U.S. arenas through and through the offset of November. Ticket prices cost betwixt $17-$55. "We want to build a fan base, have a fair-priced just the ticket and have the indicate proliferate with other versions that come out in the future," Bowen said. "We're look for an eight- to 10-year life on this show, non a quondam go-around."
The secondment leg of "Flashback" will tentatively begin in mid-February 2009, and run through early give, according to Bowen. "It's another 55 dates, but mostly in the central part of the land and the West Coast," he aforesaid.
Saturday 30 August 2008
Sunday 10 August 2008
First Step Towards Switching Off Breast Cancer And Leukaemia
�Australian scientists have identified a way to 'switch off' a molecule, a
key histrion in the molecular processes that induction breast crab and certain
forms of leukaemia.
The molecule, known as Gab2, operates downstream of a major breast cancer
oncogene, HER2, the target of the drug Herceptin.
A research team from the Garvan Institute of Medical Research, lED by
Professor Roger Daly, has establish a novel way of blocking signals to and from
Gab2, preventing it from fulfilling its part in cell proliferation. The
finding is published on-line in the EMBO Journal.
In 2002, Professor Daly identified the important role of Gab2 in boob
cancer. His task since then has been to work out exactly how Gab2 functions,
and how to closure it.
"Gab2 is a signalling protein, which substance that it's involved in
transmitting signals from the cell surface to the interior of the cell,
instructing it to do specific things, such as divide or migrate" he said.
"Gab2 performs a number of signalling roles in normal cells passim the
body, and is usually switched off when it's not needed. Our task has been to
work out how the body switches off Gab2, so that we can mimic that process
in abnormal cells."
"We've identified a completely novel mechanism for shift off Gab2. This
uses another molecule that attaches to Gab2 and acts as a kind of shield,
preventing it from transmitting further proliferative signals."
"This binding partner, or 'off switch', is called 14-3-3, and is secondhand to
incapacitate Gab2 in a number of cellular settings, when it is no thirster needed."
"As Gab2 plays key roles in signalling systems that underpin both normal
physiological responses and oncogenesis, it's very important to understand
its control mechanisms."
"Our next step will be to obtain more structural information about how
14-3-3 shields Gab2. Once we know that, it should be possible to purpose
drugs to combat Gab2-activated diseases in novel ways."
About Garvan
The Garvan Institute of Medical Research was founded in 1963. Initially a
inquiry department of St Vincent's Hospital in Sydney, it is at present one of
Australia's largest medical inquiry institutions with approximately 400
scientists, students and support staff. Garvan's main research programs ar:
Cancer, Diabetes & Obesity, Immunology and Inflammation, Bone, and
Neuroscience. Garvan's mission is to make significant contributions to
medical science that testament change the directions of science and medicine and
have major impacts on human health. The termination of Garvan's discoveries is
the development of wagerer methods of diagnosis, treatment, and at last,
prevention of disease.
The Garvan Institute of Medical Research
View do drugs information on Herceptin.
More info
key histrion in the molecular processes that induction breast crab and certain
forms of leukaemia.
The molecule, known as Gab2, operates downstream of a major breast cancer
oncogene, HER2, the target of the drug Herceptin.
A research team from the Garvan Institute of Medical Research, lED by
Professor Roger Daly, has establish a novel way of blocking signals to and from
Gab2, preventing it from fulfilling its part in cell proliferation. The
finding is published on-line in the EMBO Journal.
In 2002, Professor Daly identified the important role of Gab2 in boob
cancer. His task since then has been to work out exactly how Gab2 functions,
and how to closure it.
"Gab2 is a signalling protein, which substance that it's involved in
transmitting signals from the cell surface to the interior of the cell,
instructing it to do specific things, such as divide or migrate" he said.
"Gab2 performs a number of signalling roles in normal cells passim the
body, and is usually switched off when it's not needed. Our task has been to
work out how the body switches off Gab2, so that we can mimic that process
in abnormal cells."
"We've identified a completely novel mechanism for shift off Gab2. This
uses another molecule that attaches to Gab2 and acts as a kind of shield,
preventing it from transmitting further proliferative signals."
"This binding partner, or 'off switch', is called 14-3-3, and is secondhand to
incapacitate Gab2 in a number of cellular settings, when it is no thirster needed."
"As Gab2 plays key roles in signalling systems that underpin both normal
physiological responses and oncogenesis, it's very important to understand
its control mechanisms."
"Our next step will be to obtain more structural information about how
14-3-3 shields Gab2. Once we know that, it should be possible to purpose
drugs to combat Gab2-activated diseases in novel ways."
About Garvan
The Garvan Institute of Medical Research was founded in 1963. Initially a
inquiry department of St Vincent's Hospital in Sydney, it is at present one of
Australia's largest medical inquiry institutions with approximately 400
scientists, students and support staff. Garvan's main research programs ar:
Cancer, Diabetes & Obesity, Immunology and Inflammation, Bone, and
Neuroscience. Garvan's mission is to make significant contributions to
medical science that testament change the directions of science and medicine and
have major impacts on human health. The termination of Garvan's discoveries is
the development of wagerer methods of diagnosis, treatment, and at last,
prevention of disease.
The Garvan Institute of Medical Research
View do drugs information on Herceptin.
More info
Subscribe to:
Posts (Atom)